Pages that link to "Q28475076"
Jump to navigation
Jump to search
The following pages link to The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial (Q28475076):
Displaying 50 items.
- Targeted DNA mutagenesis for the cure of chronic viral infections (Q24620150) (← links)
- HIV-1 integrase inhibitor resistance and its clinical implications (Q24628743) (← links)
- Animal Models for HIV Cure Research (Q26767476) (← links)
- Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure (Q26781275) (← links)
- Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence (Q26801286) (← links)
- Redefining the viral reservoirs that prevent HIV-1 eradication (Q26827255) (← links)
- The immunological synapse: the gateway to the HIV reservoir (Q27002959) (← links)
- Recent developments in human immunodeficiency virus-1 latency research (Q27013114) (← links)
- New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond (Q27027164) (← links)
- Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers (Q27312050) (← links)
- Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model (Q27335485) (← links)
- A Review of Management of Inflammation in the HIV Population (Q28078962) (← links)
- Achieving HIV-1 Control through RNA-Directed Gene Regulation (Q28080090) (← links)
- Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure (Q28477257) (← links)
- Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis (Q28484930) (← links)
- Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution (Q28539563) (← links)
- HIV drug resistance mutations in proviral DNA from a community treatment program (Q28543156) (← links)
- Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (Q28551642) (← links)
- Review: Influence of ART on HIV genetics (Q28649848) (← links)
- Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 (Q28655602) (← links)
- Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals (Q28730050) (← links)
- Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA (Q28731610) (← links)
- Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected (Q28741704) (← links)
- Eradication therapies for HIV Infection: time to begin again (Q30399588) (← links)
- DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. (Q30408029) (← links)
- HIV integrase inhibitors: a new era in the treatment of HIV. (Q30956943) (← links)
- Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. (Q33585386) (← links)
- Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure (Q33593633) (← links)
- Immune activation and HIV persistence: considerations for novel therapeutic interventions (Q33698781) (← links)
- Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients (Q33798584) (← links)
- Residual immune dysregulation syndrome in treated HIV infection (Q34020121) (← links)
- Gene therapy strategies: can we eradicate HIV? (Q34165454) (← links)
- Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice (Q34180174) (← links)
- HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability (Q34244228) (← links)
- Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. (Q34249596) (← links)
- An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription (Q34289422) (← links)
- Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia (Q34324005) (← links)
- Immune activation and HIV persistence: implications for curative approaches to HIV infection (Q34351320) (← links)
- HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy (Q34354110) (← links)
- HIV-1 continues to replicate and evolve in patients with natural control of HIV infection (Q34416428) (← links)
- Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy (Q34485122) (← links)
- Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases (Q34539993) (← links)
- Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies (Q34607763) (← links)
- Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals (Q34612385) (← links)
- Immunologic basis of cardiovascular disease in HIV-infected adults (Q34638205) (← links)
- Towards an HIV cure: a global scientific strategy (Q34640562) (← links)
- Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients (Q34700900) (← links)
- A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response (Q34743336) (← links)
- Persistent immune activation in chronic HIV infection: do any interventions work? (Q34851102) (← links)
- Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens (Q34869426) (← links)